Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin,Journal of Liposome Research

当前位置： X-MOL 学术 › J. Liposome Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin
Journal of Liposome Research ( IF 3.6 ) Pub Date : 2019-11-12 , DOI: 10.1080/08982104.2019.1682604
Alina Sesarman _{1,

2,

3} , Dana Muntean ₃ , Bianca Abrudan ₃ , Lucia Tefas ₃ , Bianca Sylvester ₃ , Emilia Licarete _{1,

2} , Valentin Rauca _{1,

2} , Lavinia Luput _{1,

2} , Laura Patras _{1,

2} , Manuela Banciu _{1,

2} , Laurian Vlase ₃ , Alina Porfire ₃

Affiliation

The goal of the current study was to investigate the pharmacokinetic profile, tissue distribution and adverse effects of long-circulation liposomes (LCL) with curcumin (CURC) and doxorubicin (DOX), in order to provide further evidence for previously demonstrated enhanced antitumor efficacy in colon cancer models. The pharmacokinetic studies were carried out in healthy rats, following the i.v. injection of a single dose of LCL-CURC-DOX (1 mg/kg DOX). For the tissue distribution study, DOX concentration in tumors, heart and liver were measured after the administration of two i.v. doses of LCL-CURC-DOX (2.5 mg/kg DOX and 5 mg/kg CURC) to Balb/c mice bearing C26 colon tumors. Markers of murine cardiac and hepatic oxidative status were determined to provide additional insights into the benefit of co-encapsulating CURC and DOX in LCL over DOX-induced adverse effects in these organs. The current study demonstrated that the liposomal association of CURC and DOX effectively improved the pharmacokinetics and biodistribution of DOX, limiting its side effects, via CURC-dependent antioxidant effects.

更新日期：2019-11-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11